Document Detail

Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis.
MedLine Citation:
PMID:  17276778     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Recombinant human erythropoietin is commonly used for treatment of anaemia. Our aim was to determine whether targeting different haemoglobin concentrations with such treatment is associated with altered all-cause mortality and cardiovascular events in patients with anaemia caused by chronic kidney disease. METHODS: We did a meta-analysis of randomised controlled clinical trials that were identified in medical databases and trial registration websites. Trials were eligible for inclusion if they assessed the effects of targeting different haemoglobin concentrations in patients with anaemia caused by chronic disease who were randomly assigned to treatment with recombinant human erythropoietin, recruited at least 100 patients, and had a minimum follow-up of 12 weeks. FINDINGS: We analysed nine randomised controlled trials that enrolled 5143 patients. There was a significantly higher risk of all-cause mortality (risk ratio 1.17, 95% CI 1.01-1.35; p=0.031) and arteriovenous access thrombosis (1.34, 1.16-1.54; p=0.0001) in the higher haemoglobin target group than in the lower haemoglobin target group in the fixed effects model without heterogeneity between studies. There was a significantly higher risk of poorly controlled blood pressure (1.27, 1.08-1.50; p=0.004) in the higher haemoglobin target group than in the lower target haemoglobin group with the fixed effects model; however, this was not significant in the random effects model (1.31, 0.97-1.78; p=0.075). The incidence of myocardial infarction was much the same in the two groups. INTERPRETATION: To target higher haemoglobin concentrations when treating patients with anaemia caused by chronic kidney disease with recombinant human erythropoietin puts such patients at increased risk of death. Current guidelines do not include an upper limit for the target haemoglobin concentration; such an upper limit should be considered in future recommendations.
Arintaya Phrommintikul; Steven Joseph Haas; Maros Elsik; Henry Krum
Related Documents :
22271898 - Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia ...
3548298 - Analysis of reported randomized trials of streptokinase therapy for acute myocardial in...
7824868 - Comparison of sequential and fixed-sample designs in a controlled clinical trial with l...
12804408 - Antibiotics versus placebo for prevention of postoperative infection after appendicectomy.
20494758 - Factors influencing corneal biomechanical changes after microincision cataract surgery ...
9930158 - Latanoprost accelerates disruption of the blood-aqueous barrier and the incidence of an...
Publication Detail:
Type:  Journal Article; Meta-Analysis    
Journal Detail:
Title:  Lancet     Volume:  369     ISSN:  1474-547X     ISO Abbreviation:  Lancet     Publication Date:  2007 Feb 
Date Detail:
Created Date:  2007-02-05     Completed Date:  2007-02-16     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  2985213R     Medline TA:  Lancet     Country:  England    
Other Details:
Languages:  eng     Pagination:  381-8     Citation Subset:  AIM; IM    
NHMRC Centre of Clinical Research Excellence in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University, Alfred Hospital, Melbourne, Australia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anemia / drug therapy,  etiology*
Blood Pressure / drug effects
Cardiovascular Diseases / etiology*,  mortality
Erythropoietin, Recombinant / adverse effects*,  therapeutic use
Hemoglobins / drug effects*
Kidney Failure, Chronic / complications*
Middle Aged
Randomized Controlled Trials as Topic
Risk Factors
Reg. No./Substance:
0/Erythropoietin, Recombinant; 0/Hemoglobins
Comment In:
Lancet. 2007 May 5;369(9572):1515-6; author reply 1516-7   [PMID:  17482977 ]
Lancet. 2007 May 5;369(9572):1516; author reply 1516-7   [PMID:  17482978 ]
Lancet. 2007 May 5;369(9572):1515; author reply 1516-7   [PMID:  17482976 ]
Lancet. 2007 May 5;369(9572):1517   [PMID:  17482981 ]
Lancet. 2007 Feb 3;369(9559):346-50   [PMID:  17276756 ]
Lancet. 2007 May 5;369(9572):1517   [PMID:  17482980 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Targeted reinnervation for enhanced prosthetic arm function in a woman with a proximal amputation: a...
Next Document:  Cost-effectiveness of pneumococcal conjugate vaccination in the prevention of child mortality: an in...